Skip to content

Exploring the Effects of Corticosteroids on the Human Hippocampus

Exploring the Effects of Corticosteroids on the Human Hippocampus Using Neurocognitive Testing and High Resolution Neuroimaging

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03896659
Enrollment
66
Registered
2019-04-01
Start date
2019-10-01
Completion date
2024-09-16
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Healthy Volunteers, Hydrocortisone

Brief summary

Chronic corticosteroid (CS) exposure is associated with changes in memory and the hippocampus in both humans and in animal models. The hippocampus has a high concentration of glucocorticoid receptors (GCRs), and the pre-clinical literature demonstrates shortening of apical dendrites in the CA3 region of the hippocampus and decreased neurogenesis in the dentate gyrus (DG) following CS administration. In humans, both stress and CS exposure are associated with a decline in declarative memory performance (a process mediated by the hippocampus). Impairment in declarative memory and hippocampal atrophy are reported in patients with excessive CS release due to Cushing's disease, and, by our group, in patients receiving prescription CS therapy. These findings have important implications for patients with mood disorders, as a large subset of people with major depressive disorder (MDD) show evidence of HPA axis activation, elevated cortisol and, importantly, resistance to the effects of CSs on both the HPA axis and on declarative memory. Thus, resistance to corticosteroids appears to be a consequence of MDD. this study will examine changes in declarative memory, as well as use state-of-the-art high-resolution multimodal neuroimaging, including structural and functional (i.e., task-based and resting state) MRI, in both men and women healthy controls, and, as an exploratory aim, a depressed group, given 3-day exposures to hydrocortisone (160 mg/day) or placebo. The study will translate preclinical findings to humans, provide valuable data on possible sex differences in the response to cortisol and, for the first time, identify specific hippocampal subfields (e.g., CA3/DG) in humans that are most sensitive to acute CS effects. Using resting state fMRI data and whole brain connectomics using graph theoretical approaches, we will determine the effects of cortisol exposure on functional brain networks. Furthermore, this will be the first study to use neuroimaging to compare the brain's response to CSs in people with depression vs. controls, and determine whether depressed people demonstrate glucocorticoid resistance within the hippocampus. We hypothesize that hippocampal response to acute CSs will be greatest in the CA3/DG subfield, greater in women than in men, and that depressed people will show a blunted hippocampal response to CSs compared to controls. A multidisciplinary research team with extensive experience in CS effects on the brain and hippocampal subfield neuroimaging, and a prior history of research collaboration, will conduct the project.

Interventions

Hydrocortisone 160 mg tablet

DRUGPlacebo Oral Tablet

Hydrocortisone-matched Placebo tablet

Sponsors

University of California, Irvine
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women age 18-50 years with vision corrected to at least 20-40 (needed for fMRI tasks) * Education of ≥ 12 years * Baseline RAVLT total words recalled T-score ≥ 40 (normal range) * BMI between 18.5-35.0 (neither underweight nor severely obese) * Baseline QIDS-C ≤ 5 (virtual absence of depressive symptoms) for healthy controls and for the depressed group a QIDS-C between 11-20 (≥ moderate depressive symptoms but \< very severe depressive symptoms)

Exclusion criteria

* History of major psychiatric illness other than MDD for the depressed group, defined as bipolar disorder, posttraumatic stress disorder, schizoaffective disorder, schizophrenia, eating disorders, or MDD with psychotic features. For the control group, a past episode of MDD (per SCID) is also exclusionary * History of drug or alcohol use disorder * History of neurological disorders including seizures, brain surgery, multiple sclerosis, Parkinson's disease * Taking CNS-acting medications (e.g., antidepressants, antipsychotics, lithium, anticonvulsants, sedative/hypnotic/anxiolytics). Thus, the depressed group will be medication free. * History of allergic reaction or medical contraindication to hydrocortisone * Metal implants, claustrophobia, or other contraindications to MRI * Significant medical conditions (e.g., cancer, heart disease, diabetes) * Vulnerable population including pregnant or nursing women, prisoners, and people with intellectual disability, history of special education classes, dementia, or other severe cognitive disorders * Current suicidal ideation, a suicide attempt in the past 12 months or more than one lifetime attempt * History of systemic CS use in the past 12 months, lifetime cumulative use of more than 12 weeks, or recent (defined as past 28 days) inhaled CS use * Women who are using estrogen containing oral contraceptive agents (other contraceptives are acceptable, see Protection of Human Subjects section for a list of acceptable birth control methods) or who are post- or peri-menopausal or with irregular menstrual cycles (i.e., inconsistent menstruation patterns)

Design outcomes

Primary

MeasureTime frameDescription
Hippocampal Subfield Activation (Left Hemisphere)3 daysThe z-scores of hippocampal subregions and hemispheres represent the standardized difference in activation between correct and incorrect conditions of the mnemonic discrimination task, where a Z-score of 0 represents the mean difference across all voxels, and each unit reflects one standard deviation from that mean. To compare brain activation between conditions, separate beta weights were estimated for correct and incorrect trials across all trials. These beta weights represent the voxel-wise blood oxygen level (BOLD)-dependent signal, reflecting changes in neural activity associated with each condition. Positive z-scores indicate greater activation for correct relative to incorrect trials, whereas negative z-scores indicate greater activation for incorrect relative to correct trials. Larger absolute z-scores indicate stronger condition-related effects; there are no established clinical thresholds for these experimental activation differences.
Hippocampal Subfield Activation (Right Hemisphere)3 daysThe z-scores of hippocampal subregions and hemispheres represent the standardized difference in activation between correct and incorrect conditions of the mnemonic discrimination task, where a Z-score of 0 represents the mean difference across all voxels, and each unit reflects one standard deviation from that mean. To compare brain activation between conditions, separate beta weights were estimated for correct and incorrect trials across all trials. These beta weights represent the voxel-wise blood oxygen level (BOLD)-dependent signal, reflecting changes in neural activity associated with each condition. Positive z-scores indicate greater activation for correct relative to incorrect trials, whereas negative z-scores indicate greater activation for incorrect relative to correct trials. Larger absolute z-scores indicate stronger condition-related effects; there are no established clinical thresholds for these experimental activation differences.
Hippocampal Subfield Volume (Left Hemisphere)3 daysHigh resolution structural neuroimaging will be used to generate regional hippocampal subfield volume.
Hippocampal Subfield Volume (Right Hemisphere)3 daysHigh resolution structural neuroimaging will be used to generate regional hippocampal subfield volume.

Countries

United States

Participant flow

Recruitment details

Study participants included healthy controls and adults with depression being treated at UT Southwestern Medical Center.

Participants by arm

ArmCount
Depressed: Hydrocortisone, Then Placebo
Participants in the Depressed' arm first received Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then received a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days.
12
Depressed: Placebo, Then Hydrocortisone
Participants in the Depressed' arm first received Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then received Hydrocortisone 160 mg tablet every day for 3 days.
11
Healthy Controls: Hydrocortisone, Then Placebo
Participants in the Healthy Controls' arm first received Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then received a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days.
22
Healthy Controls: Placebo, Then Hydrocortisone
Participants in the Healthy Controls' arm first received Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then received Hydrocortisone 160 mg tablet every day for 3 days.
21
Total66

Baseline characteristics

CharacteristicDepressed: Hydrocortisone, Then PlaceboDepressed: Placebo, Then HydrocortisoneHealthy Controls: Hydrocortisone, Then PlaceboHealthy Controls: Placebo, Then HydrocortisoneTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
12 Participants11 Participants22 Participants21 Participants66 Participants
Age, Continuous32.25 Years
STANDARD_DEVIATION 11.07
41.73 Years
STANDARD_DEVIATION 8.57
29.45 Years
STANDARD_DEVIATION 9.26
31.00 Years
STANDARD_DEVIATION 9.36
32.50 Years
STANDARD_DEVIATION 10.43
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants2 Participants8 Participants9 Participants22 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants9 Participants14 Participants10 Participants42 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants4 Participants4 Participants10 Participants
Race (NIH/OMB)
Black or African American
1 Participants5 Participants2 Participants2 Participants10 Participants
Race (NIH/OMB)
More than one race
2 Participants0 Participants2 Participants0 Participants4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
8 Participants5 Participants14 Participants15 Participants42 Participants
Sex: Female, Male
Female
9 Participants9 Participants14 Participants10 Participants42 Participants
Sex: Female, Male
Male
3 Participants2 Participants8 Participants11 Participants24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 190 / 210 / 420 / 37
other
Total, other adverse events
3 / 193 / 216 / 425 / 37
serious
Total, serious adverse events
0 / 191 / 210 / 420 / 37

Outcome results

Primary

Hippocampal Subfield Activation (Left Hemisphere)

The z-scores of hippocampal subregions and hemispheres represent the standardized difference in activation between correct and incorrect conditions of the mnemonic discrimination task, where a Z-score of 0 represents the mean difference across all voxels, and each unit reflects one standard deviation from that mean. To compare brain activation between conditions, separate beta weights were estimated for correct and incorrect trials across all trials. These beta weights represent the voxel-wise blood oxygen level (BOLD)-dependent signal, reflecting changes in neural activity associated with each condition. Positive z-scores indicate greater activation for correct relative to incorrect trials, whereas negative z-scores indicate greater activation for incorrect relative to correct trials. Larger absolute z-scores indicate stronger condition-related effects; there are no established clinical thresholds for these experimental activation differences.

Time frame: 3 days

ArmMeasureValue (MEAN)Dispersion
Depressed: HydrocortisoneHippocampal Subfield Activation (Left Hemisphere)-0.35 Z-ScoreStandard Deviation 0.76
Depressed: PlaceboHippocampal Subfield Activation (Left Hemisphere)0.03 Z-ScoreStandard Deviation 0.25
Healthy Controls: HydrocortisoneHippocampal Subfield Activation (Left Hemisphere)-0.08 Z-ScoreStandard Deviation 0.57
Healthy Controls: PlaceboHippocampal Subfield Activation (Left Hemisphere)-0.07 Z-ScoreStandard Deviation 0.53
Primary

Hippocampal Subfield Activation (Right Hemisphere)

The z-scores of hippocampal subregions and hemispheres represent the standardized difference in activation between correct and incorrect conditions of the mnemonic discrimination task, where a Z-score of 0 represents the mean difference across all voxels, and each unit reflects one standard deviation from that mean. To compare brain activation between conditions, separate beta weights were estimated for correct and incorrect trials across all trials. These beta weights represent the voxel-wise blood oxygen level (BOLD)-dependent signal, reflecting changes in neural activity associated with each condition. Positive z-scores indicate greater activation for correct relative to incorrect trials, whereas negative z-scores indicate greater activation for incorrect relative to correct trials. Larger absolute z-scores indicate stronger condition-related effects; there are no established clinical thresholds for these experimental activation differences.

Time frame: 3 days

ArmMeasureValue (MEAN)Dispersion
Depressed: HydrocortisoneHippocampal Subfield Activation (Right Hemisphere)-0.05 Z-ScoreStandard Deviation 0.47
Depressed: PlaceboHippocampal Subfield Activation (Right Hemisphere)-0.04 Z-ScoreStandard Deviation 0.41
Healthy Controls: HydrocortisoneHippocampal Subfield Activation (Right Hemisphere)-0.09 Z-ScoreStandard Deviation 0.5
Healthy Controls: PlaceboHippocampal Subfield Activation (Right Hemisphere)-0.24 Z-ScoreStandard Deviation 0.37
Primary

Hippocampal Subfield Volume (Left Hemisphere)

High resolution structural neuroimaging will be used to generate regional hippocampal subfield volume.

Time frame: 3 days

ArmMeasureValue (MEAN)Dispersion
Depressed: HydrocortisoneHippocampal Subfield Volume (Left Hemisphere)56.05 Cubic MillimeterStandard Deviation 15.67
Depressed: PlaceboHippocampal Subfield Volume (Left Hemisphere)54.65 Cubic MillimeterStandard Deviation 13.9
Healthy Controls: HydrocortisoneHippocampal Subfield Volume (Left Hemisphere)54.52 Cubic MillimeterStandard Deviation 12.43
Healthy Controls: PlaceboHippocampal Subfield Volume (Left Hemisphere)50.55 Cubic MillimeterStandard Deviation 13.78
Primary

Hippocampal Subfield Volume (Right Hemisphere)

High resolution structural neuroimaging will be used to generate regional hippocampal subfield volume.

Time frame: 3 days

ArmMeasureValue (MEAN)Dispersion
Depressed: HydrocortisoneHippocampal Subfield Volume (Right Hemisphere)65.95 Cubic MillimeterStandard Deviation 20.29
Depressed: PlaceboHippocampal Subfield Volume (Right Hemisphere)66.10 Cubic MillimeterStandard Deviation 20.68
Healthy Controls: HydrocortisoneHippocampal Subfield Volume (Right Hemisphere)65.65 Cubic MillimeterStandard Deviation 16.38
Healthy Controls: PlaceboHippocampal Subfield Volume (Right Hemisphere)62.03 Cubic MillimeterStandard Deviation 17.08

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026